COVID Monitor

Tuesday, August 10, 2021
Data as of August 9, 2021

Total Confirmed Cases and Deaths

<table>
<thead>
<tr>
<th>Worldwide</th>
<th>ASEAN+3</th>
<th>Plus-3</th>
<th>ASEAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>203,356,472 Cases</td>
<td>9,490,524 Cases</td>
<td>1,364,963 Cases</td>
<td>8,125,561 Cases</td>
</tr>
<tr>
<td>4,302,588 Deaths</td>
<td>194,712 Deaths</td>
<td>22,290 Deaths</td>
<td>172,422 Deaths</td>
</tr>
</tbody>
</table>

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

Recent Developments

Global News

- Cases in the United States more than doubled since two weeks ago, with surging hospitalization in states with low vaccination rates.
- Patients in critical care in France rose by 111, the highest daily increase since early-April. Cases rose to levels last seen in early-May, driven largely by the Delta variant.

Regional News

- **Singapore** has relaxed restrictions today, including allowing dine-in. Restrictions will be eased further on August 19 when 80 percent of the population has been vaccinated.
- **Malaysia** has eased restrictions for fully vaccinated individuals, including allowing returning residents to serve quarantine at their own residence. Further reopening will be contingent on symptomatic hospitalization and vaccination progress.
- The US CDC warned against travel to Thailand after cases surged to record high of more than 20,000 per day.
- **Cambodia** is expanding quarantine facilities at the provinces bordering with Thailand, in anticipation of the influx of workers returning from Thailand.
- Confirmed cases in Japan more than tripled since end-July following the rapid spread of the Delta variant. Tokyo remains under a fourth state of emergency, amid increasing calls for a nationwide state of emergency.

Vaccine News

- **Korea** approved Phase III trial for its first homegrown protein-based vaccine, developed by SK Bioscience. Data from early trials showed that it induced neutralizing antibodies.
- **US-based Inovio Pharmaceuticals** will launch a global late-stage trial of its vaccine candidate next month, focusing on Latin America, Asia Pacific and African regions.
ASEAN+3 and Selected Economies: Confirmed COVID-19 Cases and Deaths

Source: Haver Analytics, sourced from Johns Hopkins University; and AMRO staff calculations.

1/ Values show the 7-day average.

ASEAN+3 and Selected Economies: Total Vaccines Administered

Source: Haver Analytics, sourced from Our World in Data; and AMRO staff calculations.

Note: Single vaccination doses only. This does not measure the number of people vaccinated, as two doses are required with most available vaccines. Data is reported at irregular intervals, numbers show latest available.

ASEAN+3 and Selected Economies: Vaccinations and Aspired Population Coverage

Source: Our World in Data via Haver Analytics; various media sources; Economist Intelligence Unit; and AMRO staff estimates and calculations.

Note: Percent of population vaccinated shows total administered doses divided by two to reflect the two-dose regime of most vaccines—it does not necessarily reflect the actual number of fully vaccinated people. Aspired 2021 targets and completion dates of widespread vaccination are goals, forecasts, or estimates.